AUPH (Aurinia Pharmaceuticals) חוב לטווח קצר להון

The Aurinia Pharmaceuticals (AUPH) price chart on GURU.Markets reflects the dynamics of a specialized biopharma company whose revenue is based on the sale of an approved lupus nephritis treatment, with the metric standing at 0.03. Peter Greenleaf aims to maximize the product's commercial success by reducing costs. Following unsuccessful attempts to sell the business, Aurinia Pharmaceuticals (AUPH) shifted toward aggressive cost-cutting and independent drug promotion.

Amid market volatility, capital protection requires strict monitoring of liabilities maturing within one year relative to equity. Since Aurinia Pharmaceuticals (AUPH) has outsourced production to third-party contractors, the short-term leverage ratio is critical for assessing liquidity when settling with vendors, allowing investors to determine the business's dependence on short-term debt financing and the overall resilience of the portfolio.